|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | An oral fluoropyrimidine agent S-1 induced interstitial lung disease:A case report显示文摘A 66-year-old Japanese man with pancreatic cancer received eleven courses of gemcitabine monotherapy.The tumor responded to gemcitabine until metastatic liver tumors progressed.Subsequently,he was treated with S-1,an oral fluoropyrimidine anticancer agent,as salvage chemotherapy.Forty-two days after initiating S-1,he presented with dyspnea and fever.Chest computed tomography showed diffuse interstitial lesions with thickening of the alveolar septa and ground glass opacity.Serum KL-6 level was elevated to 1,230 U/mL and he did not use any other drugs except insulin.Thus,the development of interstitial lung disease(ILD)was considered to be due to S-1.Arterial blood oxygen pressure was 49.6 Torr in spite of oxygen administration(5 L/min).Steroid therapy improved his symptoms and the interstitial shadows on chest radiograph.Although S-1-induced ILD has mostly been reported to be mild,clinicians should be aware that S-1 has the potential to cause fatal ILD. | Hiromichi Yamane Masahide Kinugawa Shigeki Umemura Yasuhiro Shiote Kenichiro Kudo Toshimitsu Suwaki Haruhito Kamei Nagio Takigawa Katsuyuki Kiura | 2011 | World Journal of Clinical Oncology2011，2，7： | 3 |
| 2 | Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients显示文摘 | Nagio Takigawa Yoshihiko Segawa Yoshinobu Maeda | | 0，，2： | 1 |
| 3 | A phase I study of S-I with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer 显示文摘 | Nagio T Katsuyuki K Katsuyuki H | 2011 | Lung Cancer2011，71，1： | 1 |
| 4 | Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene?显示文摘 | Nobuaki Ochi Hiromichi Yamane Tomoko Yamagishi Nagio Takigawa | 2012 | Lung Cancer2012，，： | 1 |
| 5 | Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer显示文摘 | Shigeki Umemura Yoshihiko Segawa Hiroshi Ueoka Katsuyuki Hotta Katsuyuki Kiura Nagio Takigawa Masahiro Tabata Akihiro Bessho Tetsu Shinkai Mitsune Tanimoto | 2007 | Journal of Cancer Research and Clinical Oncology2007，，8： | 1 |
| 6 | Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer显示文摘 | Nobuaki Ochi Nagio Takigawa Daijiro Harada Masayuki Yasugi Eiki Ichihara Katsuyuki Hotta Masahiro Tabata Mitsune Tanimoto Katsuyuki Kiura | 2014 | Experimental Cell Research2014，，： | 1 |
| 7 | Rapid on-site evaluation with BIOEVALUATOR during endobronchial uhrasound-guided transbronehial needle aspiration for diagnosing pulmonary and mediastinal diseases显示文摘 | Daisuke M Nagio T Hirofumi I | 2014 | Ann Thorae Med2014，9，1： | 1 |
| 8 | A phase I studyof S-l with concurrent thoracic radiotherapy in elderlypatients with localized advanced non-small cell lungcancer 显示文摘 | Nagio T Katsuyuki K Katsuyuki H | 2011 | Lung Cancer2011，71，1： | 1 |
| 9 | Variant angina pectoris associated with FOLFOX4 therapy显示文摘The patient was a 71-year-old man who underwent a right hemicolectomy for ascending colon cancer(pT3,pN1,pM0) and who opted not to receive adjuvant chemotherapy.Eight months later,multiple liver metastases occurred.He therefore received FOLFOX4(5-fluorouracil/leucovorin and 85 mg/m 2 oxaliplatin) therapy,up to a total of 5 courses,and showed a partial response.While receiving the sixth course of FOLFOX4,he complained of chest pain and systemic itching approximately 15 min after the start of chemo-therapy.An electrocardiogram revealed typical signs of ischemia.Coronary arteriography showed that the coronary arteries were intact.Believing the chest pain to be merely coincidental,we continued with the same therapy.However,he again developed the same chest pain during the seventh cycle of FOLFOX4 and treatment was stopped.We concluded that the patient's symptoms were due to acute coronary syndrome(ACS) associated with the FOLFOX4 regimen.Variant angina as a type of ACS is a rare adverse effect of FOLFOX4. Clinicians should be aware of this potential adverse effect when monitoring patients receiving FOLFOX4. | Hiromichi Yamane Minoru Matsubara Shigeki Umemura Toshimitsu Suwaki Haruhito Kamei Nagio Takigawa Katsuyuki Kiura Mitsune Tanimoto | 2011 | World Journal of Gastrointestinal Oncology2011，3，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员